Regulatory circuit of p300 and DNA Methylation in cancer by Panigrahi, Gagan kumar
  
REGULATORY CIRCUIT OF P300 AND DNA 
METHYLATION IN CANCER  
 
 THESIS SUBMITTED TO 
NATIONAL INSTITUTE OF TECHNOLOGY, ROURKELA 
FOR PARTIAL FULFILLMENT 
 OF THE MASTER OF SCIENCE DEGREE IN LIFE SCIENCE 
 
 
 
 
Submitted by 
GAGAN KUMAR PANIGRAHI 
ROLL NO – 410LS2065 
 
Under the guidance of 
Dr. SAMIR KUMAR PATRA 
ASSOCIATE PROFESSOR AND HEAD 
 
 
 
          
 
DEPARTMENT OF LIFE SCIENCE 
NATIONAL INSTITUTE OF TECHNOLOGY 
ROURKELA-769008, ODISHA 
2011-2012 
   
 
 
DEPARTMENT OF LIFE SCIENCE 
 NATIONAL INSTITUTE OF TECHNOLOGY, 
ROURKELA-769008 
 
             
...............................................................................................................................  
 
Dr. Samir Kumar Patra                                                  Ref. No.   
Associate Professor and Head.                                      Date: ............................ 
 
CERTIFICATE 
This is to certify that the thesis entitled “Regulatory circuit of p300 and DNA Methylation 
in cancer” which is being submitted by Mr. Gagan kumar panigrahi, Roll No. 410ls2065, for 
the award of the degree of Master of Science from National Institute of Technology, 
Rourkela, is a record of bonafide research work, carried out by him under my supervision. 
The results embodied in this thesis are new and have not been submitted to any other 
university or institution for the award of any degree or diploma. 
 
 
                                                                               Dr. SAMIR K. PATRA 
                                                                               ASSOCIATE PROFESSOR AND HEAD, 
                                                                               Department of Life Science 
                                                                               National Institute of Technology 
                                                                               Rourkela – 769008, Odisha, India. 
................................................................................................................ 
            Phone no: 0661-2462683.                    Email: skpatra_99@yahoo.com  
DECLARATION 
I, Gagan Kumar Panigrahi, hereby declare that this project report entitled “Regulatory 
circuit of p300 and DNA methylation in cancer” is the original work carried out by me 
under the supervision of Dr. Samir K. Patra, Associate Professor and Head, Department of 
Life Science, National Institute of Technology, Rourkela. To the best of my knowledge and 
belief the present work or any other part thereof has not been presented to any other 
University or Institution for the award of any other degree. 
 
 
 
     Date:                                                          GAGAN KUMAR PANIGRAHI                    
    Place:                                            
                                                                                                                
 
 
 
 
 
 
 
 
  
ACKNOWLEDGEMENT 
 
  Accomplishment is a word which always sounds good. It is really a pleasure to see 
things done in a perfect and orderly manner. I take this opportunity to offer my gratitude to 
every person who has been a part of this project. 
First and foremost, I would like to express my sincere thanks to Dr. Samir Kumar 
Patra, Associate Professor and Head, Department of Life Science, NIT, Rourkela for 
providing me with his well-needed guidance, provocative discussions and helpful advice. I 
would like to thank him for patiently scrutinizing the preparation of this project report and 
making my work a successful and meaningful endeavor. He has shown great belief in my 
abilities and I am privileged to work under his guidance. 
I would also like to express my sincere thanks to Dr. Surajit Das, Dr. Bismita Nayak, 
Dr. Sujit Kumar Bhutia, Department of Life Science, National Institute of Technology, 
Rourkela, for guiding me and encouraging me to complete my project successfully. 
My sincere and heartfelt gratitude also goes to my lab supervisor Mr Dipta Sengupta, 
Ms Moonmoon Deb, Ms Swayamsiddha Kar as well as the other PhD scholars who have 
been a constant source of motivation and support for the whole duration of the project. 
I am genuinely appreciative of all my batch mates for their suggestions and moral 
support during my work. 
Last but not the least, I would not have been able to complete this project without the 
love and support of my parents whose unflinching faith in my abilities helped me to 
overcome many obstacles and march ahead in spite of failures. I would like to dedicate this 
project to my parents and my brother. 
 
 
 
 
  
TABLE OF CONTENTS 
 
 
SL.NO. PARTICULARS PAGE NO. 
1. Introduction 1-11 
2. Review of Literature 12-19 
3. Objectives 20 
4. Materials and methods 21-25 
5. Results and Discussion 26-29 
6. Conclusion 30 
7. References 31-35 
 
 
 
 
 
 
 
 
 
 
 
  
LIST OF FIGURES 
 
SL.NO. PARTICULARS PAGE NO. 
1 Histone acetylation by histone acetyl transferase.  6 
2 Histone acetylation: a switch between repressive and permissive 
chromatin. 
7 
3 Pattern of DNA Methylation. 11 
4 Photograph of total RNA extracted. 26 
5 Photograph of the p300 from leukemia tissue and normal tissue 
after gene-specific amplification. 
27 
6 Photograph of the DNMT1, 3A, 3B from normal tissue after 
gene-specific amplification. 
27 
7 Photograph of the DNMT1, 3A, 3B from leukemia tissue after 
gene-specific amplification. 
28 
8 Graph showing comparative study of expression level of the all 
genes under study. 
29 
 
LIST OF TABLES 
 
Sl. NO. PARTICULARS PAGE NO. 
1 
Table showing the sequence of the forward and reverse primers. 
24 
2 
3 
Hist T  Table showing PCR conditions. 
Table showing the concentration and purity of total       extracted 
RNA.                              
25 
26 
4 Table showing the concentrations of PCR products after gene-
specific amplification. 
 
28 
 
  
ABSTRACT 
 
p300 is a Histone acetyltransferase which mainly acts as a global transcriptional coactivator 
and plays important roles in various biological processes including cell proliferation, 
differentiation, and apoptosis. DNMTs faithfully replicate the existing methylation marks and 
propagate the methylation pattern across successive cell generations. Since p300 is an 
acetyltransferase it activates many genes to express, thus encouraging transcriptional activity 
whereas DNA methylation represses the expression of the genome leading to silencing of 
genes. Therefore, a homeostatic balance between the two transcriptional states is maintained 
by a co-ordinated and concerted interplay between these two opposing epigenomic 
manipulations. Hence, the aberrant activity of both p300 and DNMTs may be cause 
malignant transformation leading to cancer. The present study was carried out to investigate 
the relationship between p300 and DNMTs so as to find a correlation between their 
expression and activity in cancer tissues. The mechanisms by which the inactivation of p300 
contributes to carcinogenesis have not been fully revealed. Normally, the expression of p300 
should remain at base levels in normal tissues. In cancer cells its expression is likely to be 
higher since it is a transcriptional coactivator. The results that are obtained might be because 
of the activation of the promoter regions of p300 by some other epigenetic mechanisms such 
as DNA methylation. Further studies in this area might provide an in-depth knowledge 
regarding the above two phenomena and provide ideas about novel networking between the 
various epigenetic modifications. 
 
Key words: Histone acetylation, DNA methylation, Cancer, p300, DNA methyl transferases, 
Histone acetyl transferases. 
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1. INTRODUCTION 
 
Cell is the structural and functional unit of living organism. Cell is the basic unit of 
life which exhibit an advanced cellular organization in case of eukaryotes by containing 
diverse cell organelles. Most important and vital part of cell which direct and control all the 
cellular activities is the nucleus as it carries the genetic information of cell through the 
cellular component which is known as DNA that stands for deoxyribonucleic acid. It is made 
up of a long chain of nucleotide. DNA is the fundamental of life that is transformed to RNA 
by the process known as transcription that occurs in the nucleus. RNA formed is then 
transformed into protein in the cytoplasm by the process of translation.  
Amino acid sequence of the protein of a cell and nucleotide sequence of each and 
every RNA is encoded by a nucleotide sequence of the cell’s DNA. Gene is the segment of a 
DNA molecule that contains all the informations that is required for the synthesis of a 
biological product, including RNA or protein. There are almost 40,000 genes within a cell. 
Eukaryotic DNA is packed with proteins into structures which are themselves packed into an 
order of 30-nm fibre structure that is the DNA-protein polymer called as chromatin. 
Nucleosomes are the basic entity of DNA packaging and consist of a segment of DNA wound 
around by a histone protein core. Nucleosomes are the fundamental repeating unit in 
chromatin that comprises of 146 bp of DNA wrapped around an octamer of histone proteins. 
Octamer core contains H2A, H2B dimers and H3-H4 tetramer .This dense architecture of 
chromatin logically behaves as an important barrier to almost all cellular actions which 
require the underlying DNA. One of the most extensively studied mechanisms for changing 
chromatin structure is the post translational covalent modification of the histone amino-
terminal tails.  
Chromatin assembly refers to those process where histone H3/H4 tetramers and two 
H2A/H2B dimers are deposited successively into the newly synthesized DNA to form the 
periodic arrays of nucleosomes (Haushalter and Kadonaga, 2003; Tyler et al., 2002). 
Chromatin assembly is fundamental for the replication of eukaryotic chromosomes 
(Haushalter and Kadonaga, 2003). Factors agitated in the chromatin assembly, or more 
correctly nucleosome assembly, comprise of 2 histone chaperones and also ATP-dependent 
chromatin assembly factors (Haushalter; Kadonaga, 2003; Tyler, 2002).  
2 | P a g e  
 
Nucleosome assembly occurs in moreover DNA replication-dependent or independent 
etiquette (Haushalter; Kadonaga, 2003; Tyler, 2002). DNA replication dependent nucleosome 
congregation happens right away following DNA replication or DNA repair during the cell 
cycle. Parental histones are irregularly distributed to two daughter DNA strands at the 
replication fork, and the currently synthesized histones are deposited onto the left over 
replicated DNA strands (Haushalter and Kadonaga, 2003; Krude and Keller, 2001; Mello; 
Almouzni, 2001; Tsurimoto, 1999; Tyler, 2002).  
In incongruity, DNA replication independent nucleosome assembly happens  in 
differentiated cells that do not replicate (Ahmad; Henikoff, 2002; Ray-Gallet et al., 2002; 
Wolffe; Hansen, 2001). Histone variants seem to be involved in replication-independent 
nucleosome assembly pathway (Ahmad and Henikoff, 2002; Tagami et al., 2004). Histone 
variants, like H2A.Z and H3.3, are synthesized external of S phase and can be deposited onto 
DNA all the way through the cell cycle (Haushalter and Kadonaga; 2003).  
 
1.1. Epigenetics:  
Epi-refers to “beside”, “upon” or “beyond” and genetics is the word that reflects the 
number and types of genes inherited but epigenetics reflects the regulation of genes by 
chromatin modification. It refers to the inheritable information that is encoded by alteration 
of genes and chromatin module. Epigenetic alterations in gene expression do not cause any 
alteration in the nucleotide sequence of DNA and are therefore not considered as mutation. 
Epigenetics is the theoretical aspects of developmental biology and the strategy of genes was 
given by C.H.Waddington during 1930-1960.Epigenetic changes only influence the 
phenotype. There are basically two types of modifications related to epigenetics and they are:  
1) Histone modification  
2) DNA Methylation.  
Both can be acquired or inherited and both affect transcriptional activity by regulating the 
access of transcription factors to appropriate nucleotide sequence in gene promoters.  
Histone is a protein octamer containing two copies each of the histone proteins H2A (129 
AA), H2B (125 AA), H3 (135 AA), and H4 (102 AA). H1 is the linker histone which binds 
two DNA outside the histone core. Each of the histone contains a domain for histone-histone 
and histone-DNA interaction and NH2-terminal Lysine rich and COOH–terminal tail domain 
which can be post-transnationally modified. In biology, histones are highly alkaline proteins 
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found in eukaryotic cell nuclei that package and order the DNA into structural units called as 
nucleosomes. They are the principal protein components of chromatin acting as spools 
around which the DNA winds, and plays a vital role in gene regulation. Without these 
histones, the unwound DNA in the chromosome would be very long. For example each 
human cell is almost about 1.8 mts of DNA, but on the histones it has about 90 millimeters of 
chromatin when duplicated and condensed during the mitosis those results in about 120 
micrometers of chromosomes. Histones are extremely conserved and can be grouped into five 
major classes: H1/H5; H2A; H2B; H3; and H4. These are mainly organized into two super-
classes as follows:  
  core histones – H2A, H2B, H3 and H4  
  linker histones – H1 and H5  
 
Histone proteins are subject to a wide array of post-translational modifications including 
methylation; acetylation; phosphorylation; ubiquitination; and sumoylation occurring in the 
histone core region as well as on the N-terminal tails that protrude from the core region.  
 
1.2. Epigenetic determinants of cancer:  
Cancer is considered as an ensemble of diseases in part arising from chromosomal 
abnormalities and mutations in tumour-suppressor genes and the oncogenes. The molecular 
and cellular mechanisms in malignant cell transformation increasingly indicate that cancer is 
also, in part an epigenetic disease. Losses of any DNA methylation of CpG dinucleotides in 
cancer cells were reported; this observation of the relation between cancer and DNA 
methylation were thoroughly studied. Epigenetics field not only consist of DNA methylation 
but also includes the other modifications of histones with a role in the gene expression. 
Among severalhistone modifications; methylation and deacetylation are the epigenetic 
processes more mechanistically linked to pathogenesis (Minucci et al., 2006)  
Current evidence indicates that, this deregulation contributes to the development of 
different malignancies. It has been shown that both acetylation and methylation participates 
in tumour-suppressor gene silencing (Fahrner et al., 2002). Deeper understanding of the 
epigenetic state in cancer cell is prompting the investigators to add these different analyses 
aiming to identify these genetic determinants of the epigenetic states (Laird et al., 2005)  
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1.3. Modification of histone proteins: 
Histone modification pattern are evidently not alike among diverse types of cancers 
and even ensuing stages of cancer displays differently modified histone tails. Important task 
in tumour science is to understand how the histone modifying complexes are involved in 
epigenetic modifications, how these chromatin remodeling complexes are affected (Toyota M 
et al., 2006). Histone modifications are of following types such as:  
 
1.3. a. Histone acetylation:  
Transfer of acetyl group from its cofactor acetyl coenzyme to the amino acids of the 
histone protein is called as acetylation. This process is carried out by a group of enzymes 
called acetyltransferases. Histone acetylation usually makes the chromatin accessible to the 
transcription-activating machinery, resulting in the gene expression. Acetylation of histone 
H4 at lysine 12; have been found in regions of silent heterochromatin, thus histone 
acetylation is not always coupled with the active transcription (Ballestar E, Paz MF, Valle L, 
et al 200). Acetylation state of histones seems to regulate the inter-conversion of active and 
repressive chromatin structure, but these molecular mechanisms underlying the effects of 
histone acetylation on the state of chromatin is still not well understood. Acetylation of 
histones neutralizes positively charged lysine residues of the histone N-terminal, which 
decreases the affinity for DNA. This result in unfolding of nucleosomes and increases the 
access for transcription factors.  
 
Acetylation occurs in the specific position of histone:  
H3- Acetylation occurs in 14, 9, 18 and13th position of lysine  
H4- Acetylation occurs in 5, 8, 12, 16th position of lysine  
H2A- Acetylation occurs in 5th and 9th position of lysine  
H2B- Acetylation occurs in 5, 12, 15 and 20th position of lysine.   
 
1.3. b. Methylation:  
The transfer of methyl group from its cofactor SAM (S Adenosyl Methionine) to the 
amino acids basically arginine and lysine of histone protein is called as Methylation. 
Methylation occurs in two levels that is in the DNA level and histone level and therefore 
known as DNA Methylation and Histone Methylation. The enzymes those are involved in 
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DNA Methylation are DNMT (DNA Methyltransferase) and histone Methylation is HMT 
(Histone Methyltransferase). Methylation works as gene silencing as a result of which they 
repress the transcription process. Methylation is additional of two types i.e. genome wise 
hypomethylation and region wise hypermethylation.  
1.3. c. Histone phosphorylation:  
It is a process in which the target molecule is phosphorylated by addition of a 
phosphate group to the molecule by the help of the cofactor ATP.  
1.4. HAT (Histone acetyltransferase):  
Acetyltransferases are enzymes that catalyses the transfer of acetyl groups from acetyl 
coenzyme A to either α- amino group of N-terminal amino acids or the ε- amino group of 
internal lysine residues but N terminal acetylation occurs during translation in the majority of 
eukaryotic proteins. In those reactions acetyl coenzyme A serve as the acetyl group donor, 
and the final products are acetyl-lysine and CoA. Since cloning of the first histone 
acetyltransferases 10 years ago (Kleff et al., 1995; Brownell et al.,1996; Parthun et al., 1996), 
extensive studies have made characterization of  their biological functions, mainly in the 
budding yeast, fruit fly, and mammalian cells. It has become clear that HATs participate in 
most. The phenomenon of histone acetylation in the eukaryotic cell has been known since 
many years and from the early 1970s various HAT activities have been isolated and partially 
characterized. Each of those enzymes generally belongs to one of two categories: type A that 
is located in the nucleus and type B, located in the cytoplasm, although recent evidence 
indicates that some HAT proteins may function in multiple complexes or locations and thus 
not precisely fit these historical classification. B-typeHATs are believed to have some what 
like a housekeeping function in the cell acetylating those newly synthesized free histones in 
the cytoplasm for their transport into the nucleus where they might be deacetylated and 
incorporated into chromatin . The A-type HATs, on the other side acetylate nucleosome 
histones within chromatin in the nucleus; these HATs have been potentially linked to 
transcription and thus are of main focus.  
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Fig.1: (Histone acetylation by histone acetyl transferase, Adapted from molecular cell 
biology 2005). 
 
1.4. a. Hat family: 
The human genome contains about 30 histone acetyltransferases. However, it should 
be noted that HAT might be a misnomer in some of the cases. Most of the HATs have been 
shown to acetylate also non-histone targets and some of them may not acetylate histones at 
all in more physiological conditions (Roth et al., 2001). A number of acetylated non-histone 
proteins, such as transcription factors like importins, tubulin have been characterized in 
recent years (Roth et al., 2001). It is conceivable that acetylation also participates in, for 
example, signal transduction – perhaps it does not have as pervasive a role as protein kinases 
do, but nevertheless a substantial one (Kouzarides, 2000).  
Heterochromatin: The condensed or compact state of chromatin is known as the 
heterochromatin state. Here transcription process is mainly suppressed or blocked.  
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Fig.2: (Histone acetylation: a switch between repressive and permissive chromatin, 
Anton Eberharter & Peter B. Becker 2002). 
 
Euchromatin: The relaxed state of chromatin is known as euchromatin. Here transcription 
process is activated.  
Defects in H3 and H4 modification can have important implication in development of 
various cancers because the normal or correct regulation of heterochromatin and euchromatin 
is disrupted. The regions of heterochromatin becomes demethylated and converted to 
euchromatin as a result of which transcription is activated whereas regions of euchromatin 
becomes methylated and converted to heterochromatin as a result of which transcription is 
repressed.  
There are two main super families of HATs which have been well understood and 
characterized. They are GNAT (Gcn5-related N-Acetyltransferase) and MYST (MOZ, Ybf2-
Sas3, Sas2 and Tip60) families. Best-understood set of acetyltransferases is the GNAT 
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(Gcn5-related N-acetyltransferase) super families which have been grouped together on the 
basis of their similarity in several homology regions and acetylation-related motifs. MYST 
family members’ functions in a broad range of biological processes like gene regulation 
dosage compensation and DNA damage repair, tumorigenesis (Utley & Cote; 2003). Though 
MYST proteins seem to have varied cellular role all family members are characterized by a 
highly conserved MYST acetyltransferase domain and most MYST enzymes exist as the 
catalytic subunits of a multiprotein complex. Histone acetylation is linked to transcriptional 
activation and associated with euchromatin. In most of the cases Histone Acetylation enhance 
transcription while histone deacetylation represses the transcription process.  
HATs can also have auto-regulatory functions. (Thompson et al., 2004) showed that 
p300 contains an unstructured loop that is highly acetylated in vitro and in vivo. Hyper 
acetylation of the loop enhances the HAT activity of p300 both in vivo and in vitro, 
suggesting that HATs may be regulated like some kinases with an auto inhibitory loop 
(Thompson et al., 2004).  
After initial correlative observations (Allfrey et al., 1964), the connection between 
gene activity and histone acetylation gained further support by experiments showing that 
known transcriptional co-activators had intrinsic HAT activity (Bannister and Kouzarides, 
1996; Brownell et al., 1996 Mizzen et al., 1996; Ogryzko et al., 1996 Yang et al., 1996). 
Consequently, acetylation of histone tails as a mechanism for transcriptional activation has 
become a paradigm in the field of molecular biology, although some of the counterexamples 
show that a causal link from acetylation to gene activation is sometimes too simplified a 
model (Kurdistani et al., 2004; Wang et al., 2002).  
In mammals, two related Gcn5 acetyltransferase subclasses were described: GCN5 
and p300/CREB-binding protein-associated factor (PCAF). PCAF is also able to acetylate 
transcription related to non-histone proteins like TFIIE, TFIIF, p53, HIV tat, HMGN2 and 
HMGA1. p300/CBP is yet another family of HATs. Recombinant p300 and CBP acetylates 
amino terminal tails (Bannister AJ et al., 1996; Shikama N et al., 1997) Like PCAF; 
p300/CBP is also known to acetylate and regulate transcription-related proteins other than 
histones (Sterner DE et al., 2000). They are considered to be global transcription co-
activators playing critical roles in different cellular processes: cell-cycle, differentiation, 
apoptosis (Glass CK et al., 200) whose functions are conserved from yeast to human are; 
Hat1, Hat2 and Elp3. Yeast Hat1 and Hat2, acting on non-nucleosomal histones that are 
potentially involved in the chromatin assembly process and perhaps at the replication forks or 
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at silenced telomeres (Ruiz-Garcia AB et al., 1998). Hat1 was recently shown to be also 
involved in DNA double-strand break repair, being directly recruited to sites of DNA 
damage.  
1.5. Histone acetylation and cancer:  
Epigenetics-based mechanisms leading to carcinogenesis can be divided into three 
different categories: the first is the repression of cell cycle regulatory genes including tumor 
suppressor genes; the second is the activation of normally repressed genes; the last is the 
replacement of core histones by specifically modified histone variants.  
In the first two categories, abnormal activity of HATs and HDACs are involved, 
which seems to be because of mutations of genes encoding for these enzymes or due to their 
binding and recruiting pattern. It was observed in tumours that significant imbalance of 
acetylation and deacetylation levels take place. Amusingly the results are cell cycle arrest and 
re-differentiation or apoptosis.  
Histone acetylation plays many fundamental roles in cellular processes one of them 
being very vital to cell proliferation. It is not of surprising those mutations or chromosomal 
modifications involving HATs result in the development of malignancies.  
A characteristic feature of human leukemia is the presence of chromosomal translocations 
leading to the expression of fusion proteins whose effects may be dual. Several translocations 
can inactivate the wild-type function of HATs causing the silencing of genes regulated by 
these enzymes. On the other hand, fusion proteins may be derived from a HAT and a DNA-
binding protein which can activate genes usually not expressed. This is the case of the acute 
myeloid leukemia (AML) in which a fusion between CBP and alternatively MOZ or mixed 
lineage leukemia (MLL) have occurred. Resulting protein also acquire a new function since it 
can add acetyl groups to different substrates.  
In a recent comparative analysis of normal cells primary tumours and cancer cell 
lines, a distorted recruitment of the acetyltransferases MOZ; MOF; MORF was found in 
cancer cell lines and this correlates with a global loss of the normally acetylated H4-K16. 
This feature was shown to be a widespread hallmark of human cancer and is usually 
accompanied by trimethylation at H4-K20.  
In addition, mutations of certain HATs also cause cancer, as observed in mice and in 
several cases of human leukemia. Bi-allelic mutation of the p300 locus was identified in case 
of human epithelial cancer. Another crucial disease in which HATs are not normal is the 
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congenital Rubistein–Taybi syndrome where monoallelic mutations of both p300 and CBP 
increase susceptibility to cancer.Transcriptional coactivator p300/CBP (CREBBP) is a 
histone acetyltransferase (HAT) that regulates gene expression by acetylating histones and 
other transcription factors. Deregulation of p300/CBP HAT activity contributes to various 
diseases including cancer1–4. Sequence alignments, enzymology experiments and inhibitor 
studies on p300/CBP have led to contradictory results about its catalytic mechanism and its 
structural relation with the Gcn5.Several disease-associated mutations can also be readily 
accounted for the p300 structure. These studies cover the way for new epigenetic therapies 
involving modulation of p300/CBP HAT activity. The p300/CBP protein contains numerous 
well-defined protein interaction domains as well as a centrally located 380-residue HAT 
domain.  
1.6. DNA methylation: 
DNA methylation was first discovered in calf thymus DNA by Hotchkiss in 1948. 
Methylation of DNA is a post synthetic process catalyzed by enzymes known as DNA 
methyltransferases (DNMT1, DNMT3A, DNMT3B) specifically at promoter –CpG- rich 
sequences in the presence of cofactor S-adenosyl methionine (SAM) which donates the –CH3 
group and is converted to S-adenosyl homocystein (SAH). Genomic methylation patterns are 
established in at least two developmental periods—in germ cells and preimplantation 
embryos—generating cells with broad developmental potential. There are two patterns of 
methylation in the genome, first involves de novo methylation where new methyl marks are 
added to previously unmethylated cytosines and is catalyzed by DNMT3A and DNMT3B (de 
novo methyltransferases).The second process involves maintenance methylation where the 
existing hemi-methylated daughter strands get methylated by the maintenance 
methyltransferase DNMT1 to restore the symmetrically methylated CpG dinucleotide pair.  
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Fig.3:  (Pattern of DNA Methylation, Adapted from DNA Methylation,Fingerprints of 
the epigenome,2000). 
 
This principle form of post-replicative epigenetic programming is intricately involved 
in gene regulation and silencing in eukaryotic cells making a significant contributions to cell 
phenotype. It plays an important role in regulation of parental imprinting and stabilization of 
X chromosome inactivation as well as maintenance of the genome integrity through 
protection against endogenous retroviruses and transposons. It is also implicated in the 
development of the immune system, in brain function and behavior as well as in cellular 
reprogramming and induction of stem cell differentiation. Alternatively, abnormal DNA 
methylation patterns are associated with several human diseases like psychiatric diseases and 
diseases of the immune system. Most essentially a paradoxical alternation in the established 
DNA methylation patterns involving both gene-specific hypermethylation and genome-wide 
hypomethylation is a characteristic hallmark of cancer cells, vindicating DNA.  
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2. REVIEW OF LITERATURE 
 
Epigenetics-based mechanism leading to carcinogenesis can be alienated into three 
different categories. First and foremost is the repression of normally active genes. Second is 
the activation of normally repressed genes. The last is the substitution of core histones by 
specifically modified histone variants. In the first two categories, anomalous activity of HATs 
and HDACs is involved, which seem to be either due to mutations of genes encoding for 
these enzymes, due to their binding and recruiting patterns.  
The transcriptional coactivator, p300/CBP (CREBP) is a histone acetyltransferase 
(HAT) which regulates gene expression by acetylating the histones and other transcription 
factors. Deregulations of p300/CBP HAT action, add to different diseases collectively with 
cancer.  
The role of p300/CBP in tumour suppression had been planned based on the piece of 
information that these coactivators are embattled by viral oncoproteins and that mutation of 
p300/CBP associated with inactivation of second allele have been identified in certain type of 
carcinoma. p300/CBP activity can be under aberrant control in human disease that to 
particularly in cancer which may lead to inactivate a p300/CBP tumour-suppressor-like 
activity.  
2.1. Role of p300: 
After obtainable through a number of papers we found one thing general that p300/CBP 
is globally a transcriptional coactivator. Transcriptional coactivator’s p300 and CBP are 
enormously preserved paralogous proteins, primary identified by their relations with 
adenoviral E1A and CREB (cAMP response element binding protein) respectively (Chrivia et 
al.,1993 ;Eckner et al., 1994).  
 p300/CBP regulate gene expression throughout interactions with nuclear proteins and 
involve in a broad spectrum of biological activities, involving cell cycle regulation 
differentiation as well as apoptosis and the DNA damage response (Giordano and 
Avantaggiati,1999; Goodman and Smolik, 2000).  
  Both genes are targeted in a range of cancers: truncating and point mutations in 
epithelial cancers and translocations in leukemia. This has led to the suggestion that 
p300 and CBP may function as classical tumor suppressor genes (Gayther et al., 
2000; Iyer et al., 2004b; Ward et al., 2005).  
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  p300 and CBP function as prototype histone and factor acetyltransferases (HAT and 
FAT) by catalyzing the addition of an acetyl group to specific lysine residues on 
histones and other proteins including p53 as well as retinoblastoma (RB) and E2F 
(Gu and Roeder, 1997; Martinez-Balbas et al., 2000; Chan et al., 2001).  
  Early experiments have suggested that the two homologs play interchangeable 
actually redundant roles in cell physiology. However it is becoming gradually more 
clear that p300 and CBP have distinct and non overlapping functions in numerous 
pathways, such as the p53 response (Grossman 2001; Iyer et al., 2004).  
  Histone acetyltransferase p300 functions as a transcriptional co-activator which 
interacts with a number of transcription factor, monocytic leukemia zinc finger 
protein (MOZ) has histone acetyltransferase activity. It has been reported that the 
fusion of the MOZ gene to the p300 gene in acute myeloid leukemia with 
translocation (Kitabayahi et al., 2001). Level and state of histone acetylation are 
regulated by histone acetyltransferases (HATs) and histone deacetylases (HDACs).  
 Some HATs and HDACs interact with specific DNA-binding transcription activator 
and repressor proteins which strongly suggests they modulate transcriptional activity 
of specific promoters by regulating local histone acetylation (Struhl K et al., 1998).  
  p300 and CREB-binding protein (CBP) were initially identified as cellular proteins 
which bind to the adenovirus-E1a oncoprotein and transcription factor CREB, 
respectively. p300/CBP are functionally conserved transcriptional coactivators for a 
large number of transcription factors and have intrinsic acetyltransferase activity.  
  Deregulation of p300/CBP HAT activity contributes to various diseases including 
cancer. The p300/CBP protein contains several well-defined protein interaction 
domains as well as a centrally located 380-residue HAT domain (Fig. 1). To obtain 
direct information on p300/CBP acetyltransferase structure and enzymatic 
mechanism as well as inhibition, we prepared homogeneous p300 HAT domain for 
high-resolution X-ray structure determination.  
  The role of the transcriptional coactivator p300 in cell cycle control was not 
analyzed till then due to the lack of appropriate experimental systems. The research 
group has examined cell cycle progression of p300-deficient cancer cell lines where 
p300 disrupted either by gene targeting or knocked down using the RNAi. Despite 
the significant proliferation defects under normal growth conditions p300-deficient 
cells progress rapidly through G1 with premature S-phase entry.  
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  Accelerated G1/S transition was associated with early retinoblastoma (RB) 
hyperphosphorylation and activation of E2F targets and the p300-acetylase activity 
was dispensable since expression of a HAT-deficient p300 mutant reversed these 
changes. In vitro kinase assays showed that p300 directly inhibits cdk6-mediated RB 
phosphorylation suggesting that p300 acts in early G1 and prevent Rb 
hyperphosphorylation and delay premature S-phase entry. These results suggest that 
p300 has an important role in G1/S control and possibly by modulating Rb 
phosphorylation. Over expression of p300 in fibroblasts delays S-phase entry 
(Baluchamy et al., 2003). It is suggested that the G1/S transition is regulated through 
variable activation of c-myc and c-myc-dependent targets (Kolli et al., 2001; 
Baluchamy et al., 2003).  
2.1. a. Loss of p300 results in a G1/S transition defect:  
One possible reason for the abnormal cell cycle distribution in p300 cells is that G1 to 
S phase transition may be deregulated. Early S-phase entry in p300-deficient cells is 
associated with premature Rb phosphorylation.  
2.1. b. Early S phase entry in p300 deficient cells is associated with premature Rb 
phosphorylation  
To identify mechanisms responsible for the defect in p300-deficient cells expression 
levels of proteins known to be regulate the G1/S transition to Rb, phosphorylated-Rb, 
acetylated-RB, cyclin A, cyclin D, cyclin E, p21 were analysed in HCT116 and p300 cells 
after serum- release.  
2.1. c. p300 directly inhibits cdk6 and promotes cdk2-dependent Rb kinase activities  
The role of p300/CBP in tumour suppression has been proposed based on the fact that 
these coactivators are targeted by viral oncoproteins, and that mutations of p300/CBP 
associated with inactivation of the second allele have been identified in certain types of 
carcinoma. However mechanism by which the inactivation p300/CBP contributes to 
carcinogenesis have not been fully elucidated. The research group of Tamaki Suganuma 
focused on the understanding of p300 function in tumour suppression, particularly with 
regard to its relationship with the TGFβ and also discussed the effects of p300 mutation on 
the p53 and cell proliferation (Tamaki et al, 2008).  
A major advance in knowledge on tumour suppressor proteins was brought about by the 
finding that the retinoblastoma (Rb) and p53 tumour suppressor are target for the oncogenic 
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proteins of DNA tumour viruses. Previous studies had demonstrated that these adenovirus 
E1A, SV40 large T antigen(LT), and human papilloma virus(HPV) E7 proteins form 
complexes with Rb. Likewise, SV40 LT, adenovirus E1B, and E7 bind to p53. The 
interactions are dependent on domains in these viral oncoproteins important for their 
oncogeneic activities (Tamaki et al., 2008.).  
2.2. Mutation of p300/CBP genes in human cancer:  
Direct proof representing a role for p300 in human tumours was missing until the 
newly publication by Gayther et.al, which sturdily supported a function for p300 as a tumour 
suppressor. The authors identified truncating mutations allied with the loss of the second 
allele in tumour samples and cell lines, indicating that loss of p300 may play a role in the 
growth of a subset of human cancers. The first suggestion that p300 and CBP might regulate 
growth and function as tumour suppressors was provided by the studies of adenovirus E1A’s 
transforming like properties (Andrew C Phillips and Karen H Vousden 2000).  
Another important question to be addressed was how p300 mediate its tumour 
suppressive property. One striking hypothesis would be that, since p300 is mixed up in 
recovering the transcriptional activity of p53 [Gu W, et al., 1997], loss of its function would 
retard the ability of p53 to purpose as a tumour suppressor.  
Gayther et al., sturdily support a role for p300 as a tumour suppressor, and divulge an 
attractive dual role for CBP/p300 in the growth of human cancer and in addition to 
functioning as tumour suppressors, both CBP and p300 in certain leukaemia strains, be 
oncogenic as a result of synthesis to other proteins [Jacobson S, et al., 1999, Borrow J et al., 
1998].  
2.3. Involvement of CBP/p300 in cell growth and transformation: p300/CBP as tumor 
suppressors  
CBP and p300 take part in various tumor-suppressor pathways and these coactivators 
are vital for the deeds of many oncogenes. Whether CBP and p300 support apoptosis or cell 
proliferation appear to be highly situation dependent. (Richard H. Goodman).Several features 
of p300 and CBP suggested that these proteins may serve up as tumor suppressors, but clear 
proof for this function looked-for the studies of Kung et.al. (2000).  
Muroaka et al., (1996) recognized p300 missense mutations coupled with loss of 
heterozygosity in tumors from two patients one with that of colorectal and the another with 
gastric carcinoma, and Gayther et al. (2000) reported five more examples. The growth 
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inhibition functions of p300 and CBP are also exemplified by their exchanges with the tumor 
suppressor p53. Most of the crucial functions of p53 are thought to occur throughout its 
capacity to activate genes concerned in the response to DNA damage, such as murine double 
minute (mdm-2), p21, cyclin G, and bax. Studies from different literature have shown that 
p53 interacts with a carboxy terminal region of p300/CBP and this interaction activation the 
transcription of the p53-responsive mdm-2, p21, and bax promoters (Avantaggiati et.al,. 
1997; Gu et al. 1997; Lill et al., 1997).  
As adenovirus E1A blocks p300/CBP function (Fig.3), it has been suggested that at 
least some of its effect on cell transformation may occur by repressing the actions of p53. On 
the contrary, the growth repression activities of p300 and CBP have been endorsed to their 
ability to expand p53-mediated transcription. Addition to the transcriptional activation 
functions, p53 depressingly regulates genes whose promoters do not enclose a suitable 
binding sites. Avanaggiati et al., (1997) have suggested that association of p53 and p300 may 
account for this effect, apparently by limiting access of the coactivator to promoter-bound 
transcription factors such as AP-1.  
The human pituitary tumor transforming gene (hPTTG) serve as a indicator for 
malignancy grade in various cancers. hPTTG is involved in several cellular pathways 
together with cell transformation, apoptosis, genomic instability, mitotic control, DNA repair 
and angiogenesis induction. p300 increase the activity of hPTTG promoter/Luc. p300 induces 
the expression of hPTTG mRNA and protein. p300 improved the acetylation level of histone 
H3 at the hPTTG promoter. Histone deacetylation participate in the expression of hPTTG. ( 
Tian Li et al., 2009). 
2.4. DNA methylation and its role in transcription: 
 Cancer cells and tissues exhibit genome wide hypomethylation and regional 
hypermethylation, CpGmethylation of DNA (MeCpG-DNA) is known as the formation of a 
C–C covalent bond between the 5′-C of cytosine and the –CH3 group of S 
adenosylmethionine. Removal of the sole –CH3 group from the methylated cytosine of DNA 
is one of the many ways of DNAdemethylation which can contribute to theactivation of 
transcription. Mechanism of demethylation, the candidate enzyme(s) exhibiting direct 
demethylase activity and associated cofactors are not securely established. Genomewide 
hypomethylation can be obtained in numerous ways by inactivation of DNMT enzyme 
activity including the covalent trapping of DNMT by cytosine base analogues. Removal of 
the methyl layer could also be occurred by excision of the 5-methyl cytosine base by DNA 
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glycosylases. Importance of truly chemically defined direct demethylation of intact DNA in 
regulation of gene expression also development, cell differentiation and transformation are 
discussed in this part.  
DNA methylation function in a network of epigenetic signalling for chromatin (DNA 
and histones) modifications, nucleosome stability and activation. These networks enable 
DNA methylation to organize the rigid structure of heterochromatin, and DNA demethylation 
to a relaxed euchromatin, allowing it to participate in transcription. Understanding DNA 
methylation/ demethylation and histone codes in more detail will shed new light on 
development, in addition to on a variety of pathologic states, as well as cancer, and will 
greatly help to understanding the intrinsic robustness of cellular homeostasis. 
2.5. DNA methylation as a hallmark of chromatin modifications: 
DNA (cytosine5carbon) methylation is one of the hallmarks of mammalian chromatin 
modifications. Distinct methylation pattern can make synergistic or antagonistic interaction 
affinities for CpG islands associated with methylated or unmethylated cytosine required 
proteins, which also may dictate histone modifications and dynamic transition between 
transcriptionally silent or transcriptionally active chromatin states. Enzymes and cofactors 
linked with DNA_methylation reactions are convincing in terms of chemistry and chemical 
thermodynamics. Mechanism of demethylation, the candidate enzyme(s) exhibit direct 
demethylase activity, and linked cofactors are not firmly established. Use of azanucleosides, 
such as 5azacytidine and 5aza2′deoxycytidine (AzadC), in cell culture produces re_ 
expression of certain genes, which or else were repressed in association with 
hypermethylated CpG_rich promoters. Therefore the notion developed that AzadC is a 
demethylating agent. We discuss the broad global pictures with the fol_ lowing points: first, 
chemical definition and new advances regarding the mechanism of DNA (cytosine5carbon) 
methylation (MeCpG_DNA or MeCpNpG_DNA formation) and 
MeCpG/MeCpNpG_DNA_demethylation, and then with the mechanistic basis of inactivation 
of DNA_methyltransferase 1 by AzadC. This will clarify that: (i) AzadC has nothing to do 
with DNA_demethylation; (ii) it cannot prevent even de novo methylation in non_replicating 
cells; (iii) it can only prevent replication coupled maintenance as well as de novo 
methylations. At last, we would like to suggest that terming/designating AzadC as 
DNA_demethylating agent is a serious misuse of chemistry and chemical terminology. 
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AzadC may be applied for studying the expression profile of genes that were under 
repression status; but, certainly, AzadC is neither a demethylating agent nor can be 
considered as a classical enzyme inhibitor for the DNMTs. Inhibition of methylation by any 
means should not be misinterpreted as demethylation (Patra et al.,2008). 
2.6. DNA methylation as a molecular mark for epigenetic identification: 
Epigenetic regulations of genes by reversible methylation of DNA (at the carbon-5 of 
cytosine) and numerous reversible modifications of histones play important roles in normal 
physiology and progress, and epigenetic deregulations are associated with developmental 
disorders and various disease states, together with cancer. Stem cells have the ability to self-
renew indefinitely and similar to stem cells as well as some malignant cells have the capacity 
to separate indefinitely and are referred to as cancer stem cells. In current times, direct 
correlation between epigenetic modifications and reprogramming of stem cell and cancer 
stem cell is emerging. Main discoveries were made with investigations on reprogramming 
gene products, also identified as master regulators of totipotency and inducer of 
pluoripotency, namely, OCT4, cMYC, SOX2, Klf4. The challenge to induce pluripotency is 
the insertion of four reprogramming genes into the genome. There are constantly risks of 
silencing of these genes by epigenetic modifications in the host cells chiefly when introduced 
through retroviral techniques and in this contribution thereafter we will discuss some of the 
major discoveries on epigenetic modifications within the chromatin of various genes 
associated with cancer progression and cancer stem cells in comparison to normal 
development of stem cell. These modifications may be measured as molecular signatures for 
predicting disorders of development and for identifying disease states. 
These data recommended that the two silencing mechanisms act in similar to 
reprogram the cancer epigenome and that DNA hypermethylation may change polycomb-
based repression near key regulatory genes possibly reducing the regulatory plasticity. Any 
small mistake in these vital control systems may cause cancer. Unlike genetic alterations, 
epigenetic changes are potentially reversible. Large-scale development of small-molecule 
inhibitors of DNA and histone-modifying enzymes is now in full swing. Clear information 
about epigenetic alteration makes a glorious path in cancer biology research. In the clinic, the 
success of HDAC inhibitors and DNA demethylating agents like aza cytidine as anti-cancer 
drugs demonstrates “proof of principle” of this approach and provides great hope for the 
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development of a more comprehensive portfolio of”epigenetic drugs” in the future (Patra et 
al., 2010). 
2.7. Ras regulation of DNA methylation and cancer: 
Genome wide hypomethylation and regional hypermethylation of cancer cells and 
tissues remain a paradox, though it has received a convincing verification that epigenetic 
switching systems, including DNA-methylation. It represents a fundamental regulatory 
mechanism ,which has an impact on genome maintenance and gene transcription.  The 
Methylated cytosine residues of vertebrate DNA are transmitted by clonal inheritance 
through which the strong preference of DNA methyltransferase, DNMT1 for 
hemimethylated-DNA. The maintenance of methylation patterns is necessary for normal 
development of mice, and abnormal methylation pattern is associated 
withmanyhumantumours.DNMT1 interacts with many proteins during cell cycle progression, 
with PCNA, p53, EZH2 and HP1. Ras family of GTPases promotes cell proliferation by its 
oncogenic nature, which transmits signals by numerous pathways in both lipid raft dependent 
and independent fashion. The DNA-methylation-mediated repression of DNA-repair protein 
O6- methylguanine DNA methyltransferase (MGMT) gene and increased rate of K-Ras 
mutation at codon for amino acids 12 and 13 have been correlated with a secondary role for 
Ras-effector homologues (RASSFs) in tumourigenesis. This evidence suggest that DNA-
methylation linked repression of tumour suppressors and apoptotic genes and ceaseless 
proliferation of tumour cells are regulated in part by Ras-signaling. Controlling the Ras 
GTPase signaling might reduce the aberrant methylation and accordingly may reduce the risk 
of cancer development. 
Understanding Ras regulation of DNA-methylation in more detail will shed new light 
on a variety of pathologic states; including different cancer, and will greatly help the 
understanding of the intrinsic robustness of cellular homeostasis. It is suggestive that future 
studies with Ras-regulated chromatin dynamics and the molecular biology of DNA-
methylation may also be emphasized on the following issues: (i) chromatin activation and 
nucleosome opening in response to Ras activation; (ii) dissection of lipid raft facilitated Ras-
signaling on DNA methylation and demethylation; (iii) Precise characterization and 
identification of the downstream effectors and gene specific extinguisher of Ras-signal for 
DNA-demethylation (Patra et al., 2008). 
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3. OBJECTIVES 
 
p300 gene encodes a protein that causes histone acetyltransferase activity and thus acts as a 
global transcriptional coactivator. P300 is found to be related in many of the cellular process 
whose anomalous activity leads to many cancers, including colorectal, breast, oral etc. It is a 
tumour suppressor gene which activates the activity of p53 gene. From many experiments it 
was found that those cells or tissue having lack of p300 is leading towards cancer. We 
focused particularly on p300 to know its expression and activity. Main objective was: 
 
 Semi quantitative analysis of the expression level of histone acetyltransferase p300. 
 Semi quantitative analysis of the expression level of DNA methyltransferase 
(DNMT1, DNMT3A, DNMT3B).  
 Relationship study of p300 and DNA methyltransferase in normal and cancer cells. 
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4. MATERIALS AND METHODS 
 
4.1 Collection of Samples: 
            Blood was collected as the normal tissue from the local CWS Hospital, Rourkela, Odisha, 
stored in ice and instantly processed for better RNA extraction.  Cancer tissue (Leukemia) was 
collected from National Medical College, Kolkata and stored in RNA later (Sigma) at –200C until the 
extraction of RNA. 
4.2 Extraction of Total RNA: 
Total RNA was extracted from blood (normal) and leukemia blood using GeneJET
TM 
RNA Purification Kit (Fermentas), Manual RNA Extraction techniques and Trizol method. 
4.2.1 Extraction from Blood by RNA Purification Kit: 
The collected blood was centrifuged at 3000 rpm for 15 mins at 4° C. The supernatant 
containing the serum was separated from the pellet which contains the blood cells. The pellet 
was resuspended in 600 μl of Lysis Buffer (supplemented with 20 μl of 14.3 M β-
mercaptoethanol/1ml of Lysis Buffer) and vortexed to mix thoroughly. 450 μl of ethanol (96-
100%) was mixed with the solution. Then, about 700 μl of the lysate was transferred to a 
GeneJET
TM 
RNA Purification Column inserted in a collection tube and centrifuged at 12000 
rpm for 1 min at 4° C. The flow-through was discarded and the column was placed into a new 
2 ml RNase-free microcentrifuge tube to which 700 μl of Wash Buffer 1(supplemented with 
250 μl of ethanol for every 1ml Wash buffer 1) was added and centrifuged for 1 min at 12000 
rpm. The flow-through was discarded and 600 μl of Wash Buffer 2 (supplemented with 850 
μl of ethanol for every 0.5 μl Wash buffer 2) was added to the column. It was centrifuged at 
12000 rpm for 1 min at 4° C. The flow-through was again discarded. Centrifugation was 
again done at 12000 rpm for 1 min at 4 ° C by adding 250 μl of Wash buffer 2. The flow-
through was discarded and the column was placed to a sterile 1.5ml RNase-free eppendorf 
tube. 100 μl of nuclease-free water was added to the column and centrifuged for 1 min at 
12000 rpm to elute RNA. The RNA was stored at - 20° C for further use or immediately 
processed for cDNA synthesis. 
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4.2.2. mRNA Extraction by Manual Method: 
Chemical Reagents and Buffer:-  
Chloroform isoamyl alcohol - 49:1, Ethanol, Isopropanol, PBS, Sodium Acetate, 
Solution D(Denaturating Solutions), Guanidium Thiocyanate, Sodium Citrate, 
Sodium Lawryl Sarcosinate, β Mercaptoethanol.  
Procedure:- 
             The collected blood sample was centrifuged at 3000rpm for 10 min (room 
temperature). PBS was added and centrifuged (room temperature).The pellet was collected 
and 2ml of solution D was added for 106 cells. The cells were homogenized for 15 to 30 sec 
in room temperature. 0.1ml of 2M sodium acetate (pH-4.0), 1ml of phenol and 0.2ml of 
chloroform: isoamylalcohol per milliliter of solution D was added. It was mixed thoroughly 
by inversion. The homogenate was gently vortexed vigorously for 10 sec; the tube was 
incubated for 15 minutes on ice to permit complete dissociation of nucleoprotein complex. 
The tube was centrifuged at 9000rpm for 20 min at 4
◦
C. The extracted RNA was collected in 
the upper aqueous solution. An equal volume of isopropanol was added to the extracted RNA 
and the solution was mixed and the RNA was allowed to precipitate for 1min at -20
◦
C. RNA 
was collected by centrifugation at 9000rpm at 4
◦
C for 30 min. Isopropanol was carefully 
decanted and the RNA pellet was dissolved in 0.3ml Solution D for every 1ml of solution 
used in early step.The solution was transfered to a microfuge tube, it was vortexed well and 
the RNA was precipitated with 1 volume of isopropanol for1 hour or more at -20
◦
C. The 
precipitate RNA was collected by centrifuge at maximum speed for 10mins at 4
◦
C.The pellet 
was washed twice with 75% ethanol. It was again centrifuged and allowed to dry completely. 
4.2.3 For Extraction from Cancer tissue:  
           About 30 mg of frozen cancer tissue was taken and thoroughly homogenized using 
Lysis buffer. The homogenized tissue was transferred into a sterile 2 ml microcentrifuge tube 
containing 300 μl of Lysis Buffer (supplemented with 20 μl of 14.3 M β-
mercaptoethanol/1ml of Lysis Buffer). The mixture was thoroughly mixed by vortexing for 
10 sec. The next steps of extraction were same as that followed in the previous protocol for 
blood RNA extraction. 
 
 
23 | P a g e  
 
4.3 Quantitative Estimation of RNA Concentration by Spectrophotometric Analysis: 
The concentration of the extracted total RNA from both blood and cancer tissue was 
quantified by measuring the absorbance at 260 nm in a spectrophotometer (ELICO, BL 200 
Bio Spectrophotometer, double beam) and calculated by using the formula as given below: 
Total RNA (μg /ml) = OD260 × 40 × Dilution factor. 
4.4 Quantitative Estimation of RNA Concentration by Denaturing Gel   
Electrophoresis: 
 
The extracted RNA from both blood and cancer tissue was run on a denaturing 
agarose gel and the quantity of RNA estimated from the band intensity. For denaturation gel 
(40 ml), 0.6 g agarose (Sigma), 28.8 ml dH2O (Sigma), 7.2 ml formaldehyde (Sigma), 4 ml 
10X MOPS buffer were mixed properly. About 2 μl (2μg) of the total RNA was mixed with 
18 μl 1X Reaction Buffer (2μl of 10X MOPS Buffer, 10 μl formamide (Sigma), 4 μl 
formaldehyde, 2 μl 0.2 mg/ml Etbr (Sigma)) and incubated at 55 °C for 1 hr. It was then 
cooled on ice and loaded in the wells of the denaturing gel. 
4.5. First strand cDNA synthesis: 
Total RNA (4 g) from both blood and cancer tissue were used for first strand cDNA 
synthesis by reverse transcription using RevertAid
TM 
First Strand cDNA Synthesis Kit 
(Fermentas) in a thermocycler (Biorad). The RNA samples were incubated with 1 l of oligo 
(dT)  primers (100 μM, 0.2 μg/μl) and 12 μl of nuclease-free water at 65 C for 5 min. The 
reaction was cooled on ice to allow the primers to anneal to the RNA, then spin down and 
placed on ice again after which the following components were added to the reaction in 
order; 4 l of 5X Reaction Buffer, 1 l of RibolockTM RNase inhibitor (20 U/l), 2 l of 10 
mM dNTPs and 1.0 L of RevertAidTM M-MuLV-Reverse Transcriptase (200 U/l). The 
reagents were gently mixed and incubated for 1 hr at 42C and then at 70C for 5 min 
terminated the reaction and the synthesized cDNA was stored at –20 0 C for further use. 
4.6. Gene-specific PCR for amplification of the desired gene:- 
4.6.1 Selection of Primers: 
A set of specific forward and reverse primers for the amplification of the desired gene 
under study was selected from published papers (Boldrup L.,Christophe J.B.et al 2007). The 
cDNA of both the blood and cancer tissue synthesized were used as the template for the 
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specific primers. The constitutively expressed housekeeping gene, β-actin was taken as a 
positive control to ensure high quality. The primer sequences are mentioned in Table 1:  
Table 1. Table showing the sequence of the forward and backward primers. 
 Gene   Forward  Reverse  
    
 p300   5’GACCCTCAGCTTTTAGGAATC
C 3’  
5’TGCCGTAGCAACACA
GTGTCT3’  
    
 β-actin   5’TCTACAATGAGCTGCGTGTG3’  5’ATCTCCTTCTGCATCC
TGTC 3’  
 
                                                                                       
4.6.2 PCR mixture and conditions: 
 
PCR Mixture: - (Total 25μl)  
(i) 0.2 μM dNTP- 0.5μl  
(ii) 1.5 mM MgCl2- 1.5μl  
(iii) 1x PCR Buffer- 2.5μl  
(iv) Taq Polymearse (5U/μl)- 0.5μl  
(v) Primers (0.2μM)- 0.5μl & 0.5μl  
(vi) cDNA- 2μl  
(vii) MQ Water- 17μl  
 
             The PCR sample mixtures (25 μl), contained 17 μl of dH2O (Sigma), 2.5 μl of 1X 
PCR buffer (Sigma), 0.5 μl of dNTP (0.2 mM, Sigma), 1.5 μl of MgCl2 (1.5 mM, Sigma), 0.5 
μl each of the forward and reverse primers (0.2 μM, Sigma) p53 and 0.5 μl Taq DNA-
polymerase (1U/μl, Himedia). 2 μl of each cDNA sample was added. PCR amplifications of 
p53 and β1 integrin were performed in a thermal cycler by initial denaturation at94° C for 1 
min, followed by 30 cycles of denaturation at 94° C for 1 min, annealing at 94 ° C for 30 
seconds, and extension at 60° C for 45 secs, followed by final extension step at 72° C for 5 
mins. 
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Table 2: Table showing PCR conditions 
Event Temperature (
o
C) Time 
Denaturation 94 1 min 
2
nd
 Denaturation 94 20 sec 
Annealing 57 20 sec 
Extension 72 30 sec 
Final Extension 72 5 min 
 
4.7 Agarose Gel Electrophoresis of the PCR products: 
The generated PCR products were analyzed by electrophoresis on 1.2% agarose gel. 
Agarose gel was prepared with 1X TAE (Tris Acetate EDTA, Sigma) buffer. Before casting 
ethidium bromide (1μl of 10mg/ml stock in 30 ml) was added to the gel. 15 μl of sample 
(PCR product) was loaded to each well along with 3 μl 1 X loading dye. 5 μl of DNA marker 
(100 bp- 3 kb, Sigma). The gel was run in TAE buffer at 100 volt for 40 minutes. 
4.8 Analysis of the Relative Expression level of the different genes:  
The relative levels of expression of each gene were analyzed by taking the band 
intensity using Quantity One software, Biorad. The ratios of desired genes/β-actin product 
were subsequently calculated after subtraction of the background pixel intensity for each gene 
of interest and used to assess the differences in expression levels between normal and 
leukemia blood. 
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5. RESULTS AND DISCUSSION 
5.1. Concentration and Purity of total extracted RNA: 
The concentration and purity of extracted RNA from both normal blood and leukemia sample 
and the following results were obtained (Table 2). 
Table 3: Table showing the concentration and purity of total extracted RNA 
Tissue   Concentration. (µg/ml)   Purity 
 
260/280   260/230 
 
Blood 423.90 1.18 0.68 
 
Leukemia 561.34 1.40 0.56 
 
Agarose gel electrophoresis analysis of RNA:    
                     
 
Fig. 4 The photograph of total RNA extracted run in 1% agarose gel 
LANE 1: RNA from blood. 
LANE 2: RNA from blood. 
  LANE 3: Marker. 
1 2 3 
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Fig.5 The photograph of the p300 from leukemia tissue and normal tissue after 
gene specific amplification seen in a 1.5% agarose gel 
 
 
                                       
Fig. 6 The photograph of the DNMT1, 3A, 3B  from normal tissue after gene-
specific    amplification seen in a 1.5% agarose gel 
 
               
 
 
 
   p300   (225bp) - leukemia 
p300   (225bp) - Normal 
β Actin (663bp) 
LANE 1: DNMT 1   (445bp) - Normal 
LANE 2: DNMT 3A   (485bp) – Normal 
LANE 3: DNMT 3B (465bp) - Normal 
1
 
  
2 3 
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Fig.7 The photograph of the DNMT1, 3A,3B  from leukemia tissue after gene-specific    
amplification seen in a 1.5% agarose gel. 
 Expression analysis of the desired genes: 
After the gene-specific amplification of the given genes was done for both blood and 
cancer tissue, the concentration was checked by taking its OD260/280 in spectrophotometer. 
The following results were obtained (Table 2) and the data was plotted in the form of graph 
to do a comparative analysis of the expression level of the different genes.  
Table 4: The table shows the concentrations of PCR products after gene-specific 
amplification. 
 
Gene 
 
Concentration (μg/ml) at 
260/280 nm normal tissue 
 
Concentration (μg/ml) at 
260/280 nm cancer tissue 
DNMT1 1369 1472 
DNMT3A 1158 1262 
DNMT3B 1267 1768 
P300 1543 1864 
β-actin 1745 1882 
 
The graphs were plotted according to the data given above and the following results 
were obtained.   
 
DNMT 3B (465bp) - Leukemia 
  DNMT 3A   (485bp) - Leukemia 
  DNMT 1   (445bp) - Leukemia 
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Fig.8 Graph showing comparative study of expression level of the all genes under study 
(genes involved in epigenetic regulation) as well as β-actin in both normal & cancer 
tissue. 
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6. CONCLUSION 
 
 
It was observed that p300 was highly expressed in leukemia as compared with the 
normal blood tissue. Normally, the expression of p300 should be remaining at base levels in 
normal tissues. In case of cancer cells its expressions is expected to be higher as it is a 
transcriptional coactivator. Thus, the observation points towards the involvement of p300 in 
tumorigenesis. Similarly DNMTs were also overexpressed with respect to those of normal 
tissues hence both the p300 and DNMT are overexpressed in cancer indicating towards a 
concerted and interdependent relation between the two mechanisms. 
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